Published • loading... • Updated
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a ...
Summary by Hastings Tribune
8 Articles
8 Articles
Hastings TribuneReposted by 
Post Register
Post RegisterTeva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a ...
DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva®(denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell…
·Nebraska, United States
Read Full Article
St Catharines Standard+3 Reposted by 3 other sources
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant…
·Welland, Canada
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left3Leaning Right2Center3Last UpdatedBias Distribution38% Left, 37% Center
Bias Distribution
- 38% of the sources lean Left, 37% of the sources are Center
38% Left
L 38%
C 37%
R 25%
Factuality
To view factuality data please Upgrade to Premium
